Mixed Response on Infinity Pharma as Shares Plunge Amid Phase I Data
June 03, 2013 at 13:42 PM EDT
In reports published on Monday, Wells Fargo analyst Matthew Andrews and Piper Jaffray analyst Ian Somaiya had mixed responses on Infinity Pharma (NASDAQ: INFI ) CLL drug data. Wells Fargo calls the data "Very Solid" as its Phase 1/2 data on IPI-145 in chronic lymphocytic leukemia (CLL) continued
